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Abstract
Hypersecretion of cortisol occurs in numerous patients with major depression and normalizes with
clinical recovery during the course of chronic antidepressant treatment. These clinical data suggest
that investigation of the effects of antidepressant treatments on the regulation of the brain-
pituitary-adrenal axis may assist in elucidating the therapeutic basis of antidepressant actions. In
the present investigation, both swim stress and acute fluoxetine challenge increased release of
corticosterone and progesterone to reflect an activation of the brain pituitary-adrenal axis. The
effects of chronic antidepressant treatment (21 days) on corticosterone and progesterone secretion
induced by these challenges were investigated. Chronic fluoxetine treatment (5 mg/kg/day)
completely blocked the increased secretion of corticosterone and progesterone in response to the
acute fluoxetine challenge. Chronic treatment with desipramine, imipramine or amytriptyline (15
mg/kg/day) also markedly attenuated fluoxetine-induced corticosterone and progesterone
secretion. However, chronic treatment with the monoamine oxidase inhibitors, phenelzine (5 mg/
kg) and tranylcypromine (5 mg/kg), did not affect this hormonal response to acute fluoxetine
challenge. Plasma levels of fluoxetine after acute challenge were not significantly different for the
various chronic antidepressant treatment conditions from the chronic saline controls; therefore, an
increase in the metabolism of fluoxetine can not explain the antagonism of the fluoxetine-induced
hormonal response after chronic antidepressant treatment. In contrast to the effects of selected
antidepressants on acute fluoxetine-induced steroid release, chronic treatment with imipramine (20
mg/kg/day), fluoxetine (5 mg/kg/day) or phenelzine (5 mg/kg) did not significantly alter this swim
stress-induced corticosterone or progesterone secretion. Because chronic fluoxetine and tricyclic
antidepressant drugs blocked the acute action of fluoxetine to increase adrenal cortical secretion,
but did not alter swim stress-induced secretion of these steroids, we propose that distinct
neurochemical mechanisms control fluoxetine and swim stress-induced steroid release. We
speculate that the substantial adaptive response to those chronic antidepressant treatments, which
minimize the effect of acute fluoxetine challenge to increase in corticosterone and progesterone
secretion, may be relevant to the therapeutic actions of these drugs.
Several measures of brain-pituitary-adrenal axis function are elevated in major depressive
illness (Ettigi and Brown, 1977; Holsboer and Barden, 1996). For example, a substantial
portion of depressed patients have chronically elevated cortisol (Gibbons, 1964; Sachar,
1975) and also exhibit a subsensitive negative feedback system, as reflected by attenuated
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inhibition of cortisol secretion in response to dexamethasone (Stokes et al., 1975; Carroll et
al., 1981). Additionally, in depressed patients, cerebral spinal fluid levels of CRF are
elevated (Banki et al., 1987; Nemeroff et al., 1984) and CRF mRNA in the paraventricular
nucleus of depressed suicide victims is markedly higher than in control subjects (Raadsheer
et al., 1995). Depressed patients also exhibit a supersensitive adrenocorticotropin response
to systemically administered CRF (Holsboer et al., 1987; Schmider et al., 1995). Because
stress results in activation of the hypothalamic-pituitary-adrenal axis (Ganong and Forsham,
1960), the well-documented disturbances in the control of corticoid function in depression
suggest that depressed patients may be in a state of chronic stress (Rubin et al., 1987). In the
course of chronic antidepressant drug treatment, normalization of adrenal cortical secretion
precedes or coincides with clinical recovery from depression (Linkowski et al., 1987;
Steiger et al., 1989; Souetre et al., 1989).
In addition to stress, the brain-pituitary-adrenal axis is induced by acute treatment with
serotonin uptake inhibitors and other drugs that increase the synaptic availability of
serotonin, such as 5-hydroxytryptophan (Fuller and Snoddy, 1990). The magnitude of
increased corticosterone secretion in response to acute fluoxetine challenge is similar to that
observed by various physiological stressors (Fuller and Snoddy, 1990). The acute
corticosterone response to an antidepressant drug like fluoxetine seems paradoxical, because
normalization of cortisol levels occurs with clinical recovery after chronic antidepressant
therapy (Linkowski et al., 1987; Steiger et al., 1989; Souetre et al., 1989).
The acute neuropharmacological properties of antidepressant drugs are well characterized.
However, the immediate actions of these drugs on the function of the central nervous system
can not account directly for their clinical efficacy, because chronic antidepressant
administration is required for therapeutic effectiveness (Katz et al., 1987; Klein and Davis,
1969). This requirement for chronic antidepressant administration for therapeutic
effectiveness suggests that drug-induced neural adaptation is responsible for the therapeutic
actions of this drug class (Heninger and Charney, 1987; Duman et al., 1994). A common
adaptive response produced by chronic treatment with several classes of antidepressant
drugs, including tricyclics, MAO inhibitors and the selective serotonin uptake inhibitor
fluoxetine, is a reduction in brain of levels of mRNA for CRF in animals (Brady et al., 1991,
1992). Thus, neurochemical control of the brain-pituitary-adrenal axis presents a biological
substrate to explore the mechanism by which antidepressant action affects the elevated
activity of the brain pituitary-adrenal axis in depressive illness.
Although progesterone has been considered only as a female reproductive hormone,
elevated levels of plasma progesterone accompany the increase in corticosterone after stress
in male rats (Nequin et al., 1975; Schaeffer and Aron, 1987; Deis et al., 1989; Purdy et al.,
1991) and male humans (Breier and Buchanan, 1992). Stress-induced progesterone secretion
in male and female rats is derived from the adrenal gland, because the response is abolished
after adrenalectomy (Deis et al., 1989; Nequin et al., 1975; Purdy et al., 1991). The
physiological function of progesterone secreted from the adrenals in males and females is
presently unclear. However, it is well established that systemically circulating progesterone
can enter the brain and serve as a precursor for the synthesis of neurosteriods, which are
potent allosteric moduators of γ-aminobutyric acid receptors (Majewska et al., 1986;
Morrow et al., 1987; Purdy et al., 1991; Paul and Purdy, 1992).
The purpose of the present investigation was to assess whether chronic antidepressant
treatment would induce adaptive responses in the brain, such that corticosterone and
progesterone responses to acute challenge with fluoxetine and swim stress would be
attenuated. The swim stress protocol used was the forced swim test, a behavioral screen for
antidepressant drug activity (Porsolt et al., 1978).
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Male Charles River Sprague-Dawley (Raleigh, NC) rats were housed three per cage, given
continuous access to food (Purina rat chow) and water,- and were on a 12-hr light-dark cycle
with lights off at 1900 hr. For chronic treatments, rats were injected i.p. once a day for 21
days with drugs dissolved in 0.9% saline. Drugs were prepared at 4 mg/ml to minimize
peritoneal irritation. At the termination of the experiments, when rats weighed 300 to 380 g,
they were sacrificed by decapitation between 1300 and 1500 hr for collection of trunk blood.
Chronic antidepressant treatment and hormonal responses to acute fluoxetine challenge
Rats were injected daily for 3 weeks with imipramine-HC1 (15 mg/kg), fluoxetine (5 mg/
kg), desipramine-HC1 (15 mg/kg), amytriptyline (15 mg/kg), phenelzine (5 mg/kg) or
tranylcypromine (7 mg/kg) before the hormonal response to a challenge dose of fluoxetine
was assessed. The 5 mg/kg challenge dose of fluoxetine was chosen because preliminary
studies demonstrated that this dose induced robust secretion of corticosterone and
progesterone. Furthermore, previous work by Fuller and Snoddy (1990) had shown that this
dose was slightly submaximal. Trunk blood was collected and stored on ice until
centrifugation to allow collection of the serum. Previous work showed that peak levels of
corticosterone are obtained 40 min after i.p. injection of fluoxetine and that the levels of the
hormone remain high and constant from 40 to 60 min after injection (Fuller and Snoddy,
1990). Therefore, for the acute fluoxetine challenge, rats were injected with fluoxetine-HC1
(5 mg/kg), 20 to 24 hr after the final saline or drug injection in the 3-week drug treatment
series, and sacrificed 40 min later.
Chronic antidepressant treatment and hormonal measurement in the forced swim test
Rats were injected daily i.p for 3 weeks with 0.9% saline, imipramine-HCl (20 mg/kg) or
fluoxetine-HCl (5 mg/kg). The dose of 20 mg/kg imipramine considered the maximal dose
of the drug for chronic administration and in previous work was demonstrated to antagonize
swim stress-induced Fos (Duncan et al., 1996). Desipramine was not examined in this work
with the swim test because imipramine is metabolized to desipramine and substantial levels
of this demethylated metabolite are present in brain after administration of imipramine.
After the chronic saline or antidepressant treatment, rats were processed in the forced swim
test (Porsolt et al., 1978). For the conditioning swim on the first day of the test, the rats were
placed in the swim tanks (40 × 19 cm Plexiglas cylinders) containing water (25°C) at a
depth of 16 to 17 cm for 15 min. The final drug or saline injection was given after the
conditioning swim. On the next day, for the test swim, the rats were placed in the tanks
(25°C water) for 5 min and the duration of immobility measured. Rats were sacrificed 30, 60
or 120 min after the test swim, and trunk blood was collected and stored on ice until
centrifugation.
Measurement of serum corticosterone and progesterone
Serum levels of corticosterone and progesterone were measured with radioimmunoassay kits
(ICN Biomedicals, Inc. Costa Mesa, CA) according to the manufacturer’s instruction,
with 125I-corticosterone and 125I-progesterone. Duplicate samples for each rat were assayed
for each hormone. The approximate detection limits for the corticosterone and progesterone
were 10 and 0.1 ng/ml, respectively. There was less than 1% cross-reactivity between
corticosterone and progesterone for the respective antisera in the kits.
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Measurement of serum fluoxetine
Serum fluoxetine and norfluoxetine metabolite were determined by a high-performance
liquid chromatographic method. Fluoxetine and norfluoxetine were extracted from 100-μl
serum samples with hexane/n-butylamine (9:1) after the addition of internal standard
(imipramine) and pH adjustment with ammonium hydroxide. The organic phase was
evaporated to dryness under a gentle stream of nitrogen at room temperature. After
reconstitution with 75 μl of methanol, the sample was transferred to injection vials.
Fluoxetine, norfluoxetine and internal standard were separated on a 3-μm (4.6 × 250 mm)
Hypersil silica RP column (Keystone Scientific, Inc, Bellefonte, PA) and a mobile phase of
acetonitrile/methanol/ammonium hydroxide (860:140:5) at 2.0 ml/min. Quantitation of each
compound was performed with UV detection at 254 nm (Linear Instruments, Reno, NV) and
Chrom Perfect chromatographic software (version 2.05, from Justice Innovations, Inc.,
Mountainview, CA). Standard curves were linear from 25 ng/ml, the lower limit of
quantitation, up to 1000 ng/ml for both compounds. The within- and between-day
coefficients of variation were <9%.
Statistics
Data were analyzed by two-way analysis of variance and post hoc comparisons were made
with Tukey’s test.
Results
Effects of acute fluoxetine challenge on secretion of corticosterone and progesterone
In accord with previous results (Stark et al., 1985; Fuller and Snoddy 1990), administration
of fluoxetine (5 mg/kg) induced a robust secretion of corticosterone (fig. 1) that was similar
in magnitude to that induced by swim (compare with figs. 8–10). Additionally, just as with
stress in male rats (Purdy et al., 1991), acute fluoxetine administration resulted in an
increase in progesterone (fig. 1). To determine whether the increased secretion of these
steroids involved activation of the brain-pituitary-adrenal axis, the synthetic glucocorticoid
dexamethasone was administered 4 hr before fluoxetine injection. Dexamethasone is a
potent synthetic glucocorticoid that suppresses adrenal cortical secretion by activating
negative feedback mechanisms in the brain and pituitary gland (Meikle and Tyler, 1977).
Pretreatment of rats with dexamethasone completely blocked fluoxetine-induced increases in
corticosterone and progesterone secretion (fig. 1). These data indicate that fluoxetine
induces the secretion of these steroids via an action on the brain and/or the pituitary gland.
Effects of chronic and subchronic treatment with fluoxetine on corticosterone and
progesterone secretion in response to acute fluoxetine challenge
To evaluate the effect of chronic fluoxetine on the fluoxetine-induced increase in steroids,
rats were challenged with 5 mg/kg fluoxetine after chronic administration of 0.9% saline or
fluoxetine (5 mg/kg/day for 21 days). The fluoxetine challenge dose was given 20 to 24 hr
after the final injection in the chronic fluoxetine treatment series. Chronic treatment with
fluoxetine completely blocked the effects of the acute fluoxetine challenge on both
corticosterone and progesterone secretion (fig. 2). In contrast to the effects of chronic
fluoxetine treatment, rats injected with fluoxetine for 1 day, and challenged with 5 mg/kg
fluoxetine the next day, did not exhibit diminished hormonal responses to the fluoxetine
challenge (fig. 3).
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Effects of chronic treatment with other antidepressant drugs on acute fluoxetine-induced
corticosterone and progesterone secretion
To determine whether chronic treatment with antidepressants having pharmacological
properties different from fluoxetine would antagonize the corticosterone and progesterone
response to acute fluoxetine challenge, rats were treated chronically with various other
clinically used antidepressants before an acute fluoxetine challenge. Antidepressants chosen
for study were imipramine, desipramine, amytriptyline, tranylcypromine and phenelzine.
Imipramine and amytriptyline inhibit the uptake of both serotonin and norepinephrine
(Wood et al., 1986), whereas desipramine has predominant actions on norepinephrine
uptake with little effect on serotonin uptake (Randrup and Braestrup, 1977). Desipramine
also was chosen for study to determine whether an antidepressant drug, which does not
directly affect serotonin function, would induce an adaptive response in serotonergic control
of the brain-pituitary-adrenal axis, as assessed by the acute fluoxetine challenge. Chronic
administration of imipramine, desipramine (fig. 4) or amytriptyline (fig. 5) markedly
attenuated corticosterone and progesterone secretion induced by acute fluoxetine challenge.
In contrast to the blockade by the tricyclic antidepressants on fluoxetine-induced steroid
secretion, chronic treatment with the MAO inhibitors, tranylcypromine and phenelzine, did
not affect the hormonal response to acute fluoxetine challenge (fig. 5).
Effect of chronic antidepressant treatments on serum levels of fluoxetine
Because the reduced corticosterone and progesterone responses to acute fluoxetine challenge
could have been caused by an altered metabolism of fluoxetine during the course of the
chronic treatment of the antidepressants, plasma levels of fluoxetine were measured after
chronic antidepressant treatments that antagonized the steroid response to fluoxetine. Serum
fluoxetine levels after acute challenge were not significantly different in rats treated
chronically with saline, fluoxetine, imipramine or desipramine (fig. 6). Serum norfluoxetine
levels were significantly lower in rats treated chronically with desipramine and imipramine,
but not fluoxetine (fig. 6). However, because fluoxetine levels were not reduced in the rats
treated chronically with imipramine or desipramine, altered fluoxetine metabolism can not
explain the attenuated hormonal responses to acute fluoxetine observed after chronic
administration of these tricyclic antidepressants.
Effects of chronic treatment with fluoxetine, imipramine and phenelzine on swim stress-
induced immobility and corticosterone and progesterone secretion
To determine whether the marked reduction in fluoxetine-induced corticosterone and
progesterone secretion after chronic antidepressant treatment was caused by generalized
desensitization of the brain-pituitary-adrenal axis, the effects of chronic treatment with
imipramine and fluoxetine on swim stress-induced secretion of these hormones was
examined. No significant difference in basal or swim-induced corticosterone or progesterone
levels was observed between rats treated chronically (3 weeks) with imipramine (fig. 7),
fluoxetine (fig. 8) or phenelzine (fig. 9) and those treated with saline.
Even though no effect of chronic antidepressant treatment was found on swim-induced
steroid secretion, all three antidepressant drugs reduce the duration of immobility in the
swim test (fig. 10; Porsolt et al., 1978). As reported previously (Detke et al., 1995),
behavioral responses to fluoxetine were qualitatively distinct from the behavioral response
obtained with imipramine and phenelzine. After treatment with imipramine and phenelzine,
rats jumped from the bottom of the swim tanks and attempted to vigorously climb the walls
of the tanks for much of the nonimmobile time. In contrast, such behavior was not exhibited
by the fluoxetine-treated rats, which exhibited less vigorous “escape-directed” behavior, but
instead would swim around the tank without jumping or climbing during the nonimmobile
time. Thus, although a behavioral consequence could be elicited by the chronic
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administration of these antidepressants, their chronic treatment failed to affect the secretion
of corticosterone or progesterone in response to swim stress.
Discussion
The present studies demonstrated that acute administration of fluoxetine, as well as swim
stress, induced a robust increase in corticosterone and progesterone secretion. Because
depressed patients can have chronically elevated cortisol levels (Gibbons, 1964; Sachar,
1975), it seems paradoxical that an acute response to an antidepressant (i.e., induction of
corticosterone secretion by fluoxetine) is similar to a symptom manifested in some
depressed patients. However, the recognized requirement for chronic antidepressant
administration to achieve a therapeutic response in depressed patients, which includes a
reduction in their hypersteroid secretion, demonstrates that acute pharmacological properties
of fluoxetine do not account for the clinical efficacy of this drug class. One hypothesis tested
in the present work was that chronic treatment with antidepressants would induce adaptive
changes leading to an attenuation of the acute fluoxetine and stress-induced adrenal cortical
activation. Our goal was to characterize a model system that could be used to explore
antidepressant-induced neurochemical adaptation relevant to neural mechanism(s) by which
antidepressants reduce the hypersecretion of cortisol in depressive illness.
Acute effects of fluoxetine and swim stress on corticosterone and progesterone secretion
Other investigators previously have observed that swim stress can increase progesterone as
well as corticosterone secretion (Purdy et al., 1991). Although acute fluoxetine has been
reported to increase corticosterone secretion (Stark et al., 1985; Fuller and Snoddy, 1990),
our data are the first to demonstrate that acute fluoxetine administration also induces
secretion of progesterone. Increased progesterone secretion during the menstrual cycle and
administration of synthetic progesterone in oral contraceptives have been associated with
depressive illness in some women (Backstrom, 1995; Crammer, 1986; Wagner and
Berenson, 1994). However, many women do not experience depression while taking
progestins in oral contraceptives, and anecdotal evidence suggests that the high levels of
progesterone that exist during pregnancy are associated with a state of well-being. Thus,
additional work is required to determine the psychophysiological consequences of
alterations in progesterone levels in males and females. Little is known about the functional
consequences of increased progesterone secretion in males, but plasma-derived progesterone
can serve as a precursor in the brain for the synthesis of potent neuroactive steroids which
can affect γ-aminobutyric acid-mediated neurotransmission (Majewska et al., 1986; Morrow
et al., 1987; Purdy et al., 1991; Paul and Purdy, 1992). Such data indicate that adrenal-
derived progesterone in males could be neurochemically relevant.
Possible mechanisms of acute fluoxetine-induced corticosterone and progesterone
secretion
Inhibition of the serotonin transporter by fluoxetine results in an increased extracellular fluid
level of serotonin (Fuller and Snoddy, 1990). Therefore, the most probable mechanism by
which acute fluoxetine induces activation of the brain-pituitary-adrenal axis would be by
increasing the synaptic concentration of serotonin, with consequent increased activation of a
serotonin receptors. Nonetheless, the specific serotonergic receptor mechanism involved in
the neuroendocrine activation by fluoxetine is unknown. Both 5HT-2 and 5HT-1A receptor
agonists have been shown to increase corticosterone levels (Urban et al., 1986; Fuller et al.,
1986; Koenig et al., 1987; Fuller and Snoddy, 1990) and chronic fluoxetine treatment
reduces corticosterone secretion induced by the 5HT-1A agonists (Li et al., 1993,1994).
However, 5-HT-1A and 5HT-2 receptor antagonists do not attenuate the acute fluoxetine-
induced increase in corticosterone levels (Fuller and Snoddy, 1990). Furthermore,
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interactions between the two receptor subtypes can not explain the effects of fluoxetine on
corticosterone secretion, because coadministration of 5HT-1A and 5HT-2 receptor
antagonists also did not block this fluoxetine-induced endocrine response (Fuller and
Snoddy, 1990). Consequently, if enhancement of synaptic availability of endogenous
serotonin by the fluoxetine is responsible for the adrenal cortical activation, a serotonin
receptor subtype other than 5HT-1A or 5HT-2 may be involved. Although one potential
candidate is the recently cloned 5HT-7 receptor, which is enriched in the hypothalamus (To
et al., 1995; Sleight et al., 1995), no direct information currently documents specific 5HT
receptor subtypes in the control of fluoxetine-induced steroid release.
Effect of chronic antidepressant administration on fluoxetine-induced steroid secretion
Chronic administration of all antidepressant drug types which inhibit uptake of serotonin,
including fluoxetine (Stark et al.; 1985), imipramine and amytriptyline (Randrup and
Braestrup, 1977; Wood et al., 1986), blocked the increase in corticosterone and progesterone
induced by the acute fluoxetine challenge, without affecting base-line levels of these
steroids. Likewise, chronic administration of desipramine, which potently inhibits
norepinephrine uptake with minimal effect on serotonin uptake (Randrup and Braestrup,
1977), also antagonized fluoxetine-induced steroid secretion. These findings suggest that
chronic inhibition of either serotonin uptake or noradrenergic uptake results in adaptive
changes that markedly attenuate the ability of fluoxetine to induce secretion of
corticosterone and progesterone. Unlike the effects of chronic treatment with fluoxetine and
tricyclic antidepressant drugs, chronic treatment with the MAO inhibitors, phenelzine and
tranylcypromine, did not result in a significant attenuation of the corticosterone and
progesterone responses to the acute challenge with fluoxetine. Thus, the attenuation of
fluoxetine-induced steroid secretion is not a general feature of all antidepressant drugs.
Possible adaptive mechanisms responsible for the antagonism of the steroid release by
chronic antidepressant treatments
After chronic fluoxetine treatment, in vivo microdialysis studies have shown that
extracellular fluid levels of serotonin are markedly elevated after the last chronic fluoxetine
treatment (Rutter et al., 1994). The increased extracellular level of serotonin induced by
fluoxetine after chronic treatment was even greater than after an acute fluoxetine challenge
(Rutter et al., 1994). Thus, a reduced effectiveness of fluoxetine to release serotonin after
chronic administration does not appear to be responsible for the observed blockade of the
steroid release after acute fluoxetine administration. Additionally, serum levels of fluoxetine
after acute challenge were similar in groups treated chronically with saline or with the
antidepressants that blocked the acute steroid response to fluoxetine challenge. Therefore, an
increased metabolism of fluoxetine can not explain the antagonism of fluoxetine-induced
steroid release by chronic treatment of selected antidepressant drugs.
Chronic treatment with antidepressant drugs which block serotonin or norepinephrine uptake
sites must result in a substantial neurochemical adaptation in neural circuits which regulate
fluoxetine-induced adrenal hormone secretion, as both types of drugs antagonized this
response. Although chronic treatment with fluoxetine has been shown to reduce
corticosterone secretion induced by 5HT-1A agonists, (Li et al., 1993), chronic treatment
with desipramine, which also reduces the acute fluoxetine-induced increases in steroid
secretion, does not modify 5HT-1A agonist-induced corticosterone secretion (Li et al.,
1994). These data, considered with the data of Fuller and Snody (1990) discussed above,
suggest that the antagonism of fluoxetine-induced adrenal hormone secretion after chronic
antidepressant treatment can not be explained by a reduction in the sensitivity of 5HT-1A
receptors.
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Chronic desipramine treatment, which antagonizes fluoxetine-induced release of steroids,
causes down-regulation of beta adrenergic receptor number and function (see Baker and
Greenshaw, 1989). Although chronic fluoxetine treatment also antagonizes steroid release
by acute fluoxetine administration, chronic fluoxetine does not cause a down-regulation of
beta adrenergic receptors (Johnson, 1991). As observed for the tricyclic antidepressant drugs
(Baker and Greenshaw, 1989), chronic administration of MAO inhibitors also induces an
adaptive down-regulation of beta adrenergic receptors; however, this class of
antidepressants does not have an effect on the acute fluoxetine-induced release of steroids.
Collectively, these latter data suggest that antidepressant-induced adaptive changes in
noradrenergic receptor function can not explain the present finding that selected
antidepressant drugs block acute fluoxetine-induced release of steroids.
Chronic administration of fluoxetine, tricyclic antidepressants and MAO inhibitors has been
shown to reduce the expression of mRNA for CRF in the paraventricular nucleus of the
hypothalamus (Brady et al., 1991, 1992). However, this action is apparently not sufficient to
explain the present results, because MAO inhibitors are ineffective in reducing fluoxetine-
induced hormonal secretion. Chronic fluoxetine administration also has been shown to
down-regulate the 5-HT-7 receptor subtype in hypothalamic membrane preparations after
chronic fluoxetine treatment (Sleight et al., 1995); however, it is not known whether chronic
desipramine affects this 5-HT receptor subtype. Thus, it can be concluded that the adaptive
mechanism(s) by which chronic antidepressant treatment blocks the acute action of
fluoxetine to stimulate corticosterone and progesterone secretion has yet to be identified.
Chronic antidepressant treatments on forced swim-induced immobility and corticosterone
and progesterone secretion
The final aspect of our investigation was to determine whether chronic antidepressant
treatment would antagonize the release of corticosterone and progesterone induced by swim
stress (Purdy et al., 1991). This particular stressor was chosen because the protocol of forced
swim is used to screen for antidepressant action (Porsolt et al., 1978). As expected from
previous work (Duncan et al., 1985, 1996), chronic administration of the antidepressant
drugs fluoxetine, imipramine and phenelzine resulted in a significant reduction in the
immobility in the forced swim test paradigm. Even though chronic administration of the
antidepressants produced a behavioral change induced by forced swim, swim stress-induced
secretion of these steroids was not affected by such chronic antidepressant exposure. The
inability of chronic treatment with fluoxetine and imipramine to modify adrenal cortical
secretion in response to swim stress suggests that a generalized down-regulation of the
brain-pituitary-adrenal axis was not induced by the antidepressant drug treatments.
In contrast to the present data showing no effect of chronic antidepressant treatment on
swim-induced activation of the brain-pituitary-adrenal axis, Reul et al. (1993) found that
chronic administration of amytriptyline reduced the corticosterone response induced by
placing rats in a novel environment. Differences in the nature of these stressors and the
possible activation of differing neural pathways by the stressors could explain the ability of
chronic treatment to block the stress response induced by the novel environment but not
affect the increase in corticosterone induced by the swim. On the other hand, the magnitude
of the stress response could be a consideration, because swim stress could be expected to be
more stressful than novelty stress. In this regard, swim stress typically increased
corticosterone levels to 300 to 400 ng/ml, whereas in the study of Reul et al.(1993), the
novelty stress condition increased corticosterone to about 250 ng/ml. Thus, one
interpretation could be that chronic antidepressant treatment could not overcome the
hormonal response of the more severe swim stress compared with the stress of novel
environment. However, contrary to this interpretation, acute fluoxetine treatment increased
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steroids to a level as great as that observed with swim stress, yet this increase by the acute
fluoxetine challenge was blocked completely by the chronic antidepressant treatments.
Therefore, the differential effects observed for the antidepressant treatments on swim stress-
induced and fluoxetine-induced alterations in corticosterone and progesterone secretion may
involve differing neural mechanisms associated with regulation of adrenal steroid secretion.
In this regard, at least two distinct pathways controlling CRF release have been proposed
previously, one originating from brainstem structures and the other involving projections
from limbic regions of the forebrain (Herman and Cullinan, 1997; Sawchenko, 1990).
Whether altered activity in these distinct pathways contributes to the differential effects of
chronic antidepressant treatment on fluoxetine- and stress-induced adrenal steroid secretion
deserves investigation.
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Acute fluoxetine-induced increase in corticosterone and progesterone secretion: Effect of
dexamethasone. Rats were pretreated with saline (SAL) or dexamethasone (DEX, 0.5 mg/
kg) 4 hr before challenge with saline or fluoxetine (FLU). Rats were sacrificed 40 min after
the saline or fluoxetine challenge. Data are means ± S.E.M. with n = 6 for each group. *P < .
01 compared with SAL; **P < .01 compared with SAL-FLU.
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Effect of chronic fluoxetine treatment on corticosterone and progesterone secretion in
response to acute fluoxetine challenge. Rats were injected daily for 21 days with 0.9% saline
or fluoxetine (5 mg/kg). Twenty-four hours after the final injection, a challenge dose of
fluoxetine (5 mg/kg) or saline was administered and rats were sacrificed by decapitation 40
min later. Abbreviations: SAL, saline; FLU, fluoxetine. The number of rats in each group
are given above the bars. Data are presented as the mean ± S.E.M. for each group. *P < .01
compared with SAL-SAL; ** P < .01 compared with SAL-FLU.
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Lack of effect of 1-day fluoxetine treatment on corticosterone and progesterone secretion in
response to fluoxetine challenge. Rats were treated with fluoxetine (FLU, 5 mg/kg) or saline
(SAL) on day 1 and challenged with saline or fluoxetine (5 mg/kg) on day 2, as indicated.
SAL-FLU levels of corticosterone and progesterone after SAL-FLU were not significantly
different from levels in the FLU-FLU-treated rats.
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Effect of chronic imipramine and desipramine treatment on fluoxetine-induced secretion of
corticosterone and progesterone. Rats were injected daily for 21 days with 0.9% saline,
imipramine or desipramine (15 mg/kg for each). Twenty-four hours after the final injection
of desipramine and imipramine, a challenge dose of fluoxetine (5 mg/kg) was given and rats
were sacrificed by decapitation 40 min later. The number of rats in each group are given
above the bars. Data are presented as the mean ± S.E.M. for each group. Abbreviations:
SAL, saline; IMI, imipramine; DMI, imipramine. *P < .01 compared with SAL-SAL; **P
< .01 compared with SAL-FLU.
DUNCAN et al. Page 16














Effect of chronic amytriptyline (AMY), phenelzine (PHEN) and tranylcypromine (TRAN)
treatment on fluoxetine-induced secretion of corticosterone and progesterone. Rats were
injected daily for 21 days with either 0.9% saline, AMY (15 mg/kg), PHEN (5 mg/kg) or
TRAN (5 mg/kg). Twenty-four hours after the final injection of these chronic exposures, a
challenge dose of fluoxetine (FLU; 5 mg/kg) was given and rats were sacrificed by
decapitation 40 min later. The number of rats in each group are given above the bars. Data
are presented as the mean ± S.E.M. for each group. **P < .05 compared to SAL-FLU.
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Lack of effect of chronic treatment with desipramine (DMI), imipramine (IMP) or fluoxetine
(FLU) on serum levels of fluoxetine after acute challenge. Rats were treated as described in
figures 2 and 4. Fluoxetine and norfluoxetine levels were measured by HPLC with UV
detection in serum obtained 40 min after acute challenge with fluoxetine. The number of rats
in each group are given above the bars. Data are presented as the mean ± S.E.M. for each
group. The norfluoxetine levels were reduced significantly in the chronic DMI- and IMP-
treated rats, but not in the FLU-treated rats. *P < .05 compared with SAL-FLU.
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Lack of effect of chronic imipramine treatment on swim-induced corticosterone or
progesterone. Rats were injected daily with imipramine (20 mg/kg) for 21 days before
processing in the forced swim test as described under “Materials and Methods.” After the
test swim (20–24 hr after the final drug or saline injection), the rats were transferred to their
home cages and sacrificed by decapitation at the indicated times after the swim for
collection of trunk blood. Rats that received chronic injections of saline or imipramine and
were not swum were sacrificed 20 to 24 hr after the final injection. The number of rats for
each time and treatment are indicated above the bars. Data are expressed as the mean ±
S.E.M. for each group.
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Lack of effect of chronic fluoxetine treatment on swim-induced corticosterone or
progesterone. Rats were injected daily with fluoxetine (5 mg/kg) for 21 days before
processing in the forced swim test as described under “Materials and Methods.” After the
test swim (20–24 hr after the final drug or saline injection), the rats were transferred to their
home cages and sacrificed by decapitation at the indicated times after the swim for
collection of trunk blood. Rats that received chronic injections of saline or fluoxetine and
were not swum were sacrificed 20 to 24 hr after the final injection. The number of rats for
each time and treatment are indicated above the bars. Data are expressed as the mean ±
S.E.M. for each group.
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Lack of effect of chronic phenelzine treatment on swim-induced corticosterone or
progesterone. Rats were injected daily with phenelzine (PHEN, 5 mg/kg) for 21 days before
processing in the forced swim test as described under “Materials and Methods.” After the
test swim (20–24 hr after the final drug or saline injection), the rats were transferred to their
home cages and sacrificed by decapitation at the indicated times after the swim for
collection of trunk blood. Rats that received chronic injections of saline or phenelzine, and
were not swum, were killed 20 to 24 hr after the final injection. The number of rats for each
time and treatment are indicated above the bars. Data are expressed as the mean ± S.E.M.
for each group.
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Immobility time for rats processed in the forced swim test after chronic antidepressant
treatment. Rats were injected with saline (SAL), imipramine (IMI, 20 mg/kg) or fluoxetine
(FLU, 5 mg/kg) and immobility time scored in the test swim (see “Materials and Methods”).
****P < .001,*P < .05 compared with saline.
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